| Completed | Open-Label Extension Study for Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Complet Chronic Spontaneous Urticaria | Phase 1 | 2024-08-28 |
| Completed | Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Healthy Participants, Chronic Spontaneous Urticaria | Phase 1 | 2023-08-28 |
| Terminated | A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria Chronic Spontaneous Urticaria | Phase 2 | 2022-10-26 |
| Terminated | A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis Atopic Dermatitis | Phase 2 | 2022-06-27 |
| Withdrawn | A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis Eosinophilic Gastritis, Eosinophilic Duodenitis | Phase 3 | 2021-12-01 |
| Completed | A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis Eosinophilic Duodenitis, Eosinophilic Gastroenteritis | Phase 3 | 2021-05-20 |
| Completed | An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred Eosinophilic Gastritis, Eosinophilic Duodenitis | Phase 3 | 2020-12-03 |
| Completed | A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis Eosinophilic Esophagitis | Phase 2 / Phase 3 | 2020-07-06 |
| Completed | A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosi Eosinophilic Gastritis, Eosinophilic Duodenitis | Phase 3 | 2020-06-18 |
| Completed | A Study to Evaluate Safety, Tolerability, and Bioavailability of Subcutaneous Lirentelimab (AK002) in Adult He Study Conducted in Healthy Volunteers | Phase 1 | 2020-03-23 |
| Completed | An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Duodenitis | Phase 2 | 2018-11-14 |
| Completed | A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Eosinophilic Gastritis, Eosinophilic Gastroenteritis | Phase 2 | 2018-07-18 |
| Completed | A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Alle Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, Perennial Allergic Conjunctivitis | Phase 1 | 2018-02-26 |
| Completed | A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria Chronic Urticaria | Phase 2 | 2018-01-23 |
| Completed | Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AK002 in Healthy Participants Healthy | Phase 1 | 2016-08-01 |
| Completed | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 Indolent Systemic Mastocytosis | Phase 1 | 2016-06-01 |
| Completed | Study to Evaluate Multiple Doses in Patients With Nasal Polyposis Nasal Polyposis | Phase 2 | 2016-04-01 |
| Completed | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK001 Atopy | Phase 1 | 2015-09-01 |